pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
COMPANY OVERVIEW
Atox Bio is a late stage clinical biotechnology company that develops novel immune modulators for critically ill patients with severe infections.
LOCATION
Ness Ziona, , Israel
Chapel Hill, NC, USA
THERAPEUTIC AREAS
Infectious Disease
Kidney Disease
WEBSITE
https://www.atoxbio.com
CAREER WEBSITE
None
SOCIAL MEDIA
INVESTORS
PRESS RELEASES
Dec 10, 2020
Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection ("Flesh-Eating Disease") USA - English Israel - English
Jun 18, 2019
Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI
Jun 18, 2019
Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI
Feb 14, 2019
Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer
Feb 14, 2019
Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer
For More Press Releases